Interstitial pneumonitis associated with dasatinib: two case reports and literature review

Publication date: Available online 13 July 2019Source: Respiratory InvestigationAuthor(s): Yuhei Ito, Motoaki Tanigawa, Keisuke Iwamoto, Akina Nigi, Hidetoshi Itani, Shigeto Kondo, Toshiya Tokui, Eiji Usui, Shigehisa TamakiAbstractDasatinib has increasingly been used to treat chronic myeloid leukemia (CML), although interstitial pneumonitis has been found as a complication in large clinical trials. In the present study, 23 patients received dasatinib for CML between 2012 and 2017 at our institution, of whom 2 developed symptomatic interstitial pneumonitis. Notably, the first patient developed interstitial pneumonitis five years after initiating dasatinib. Interstitial pneumonitis should be considered as a complication in patients receiving dasatinib for CML, which may even occur after a long period of uncomplicated administration.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research